CNS Disease Opportunities in China
China biotech companies are gearing up to step into the CNS field through building their own platforms and creating cross-border partnerships. Despite high risks, the rewards of developing the next neurology remedies appear to be much higher, encouraging biotech and biopharma players to keep one foot sturdily in the door when it comes to neuro-pharma development. Platform progress is opening the door for CNS dealmaking. Big biotechs expand their neurology pipeline through cross-border partnerships.
REPORT HIGHLIGHTS
The rising demand for effective CNS therapeutic choices is pushing big pharma to engage in research and development, paving the way for future growth
Advancements in diagnostics, treatments, and drug discovery methodologies are driving the growth of the central nervous system therapeutics market
Global demand for the treatment of Parkinson’s and Alzheimer’s diseases is expected to witness extensive growth
China has ~95M depressive disorder patients and the current cognitive and diagnostic rate is relatively low
Many Chinese companies are getting into CNS diseases areas through cross-border partnerships